

Characterization of protein complexes using chemical cross-linking coupled electrospray mass spectrometry

Timothy D. Cummins* and Gopal P. Sapkota*

Medical Research Council Protein Phosphorylation and Ubiquitylation Unit,
University of Dundee, Dow St., Dundee DD1 5EH, UK

*Address correspondence to t.cummins@dundee.ac.uk and g.sapkota@dundee.ac.uk

Abstract

Identification and characterization of large protein complexes is a mainstay of biochemical toolboxes. Utilization of cross-linking chemicals can facilitate the capture and identification of transient or weak interactions of a transient nature (1, 2). Here we describe a detailed methodology for cell culture based proteomic approach. We describe the generation of cells stably expressing green fluorescent protein (GFP)-tagged proteins under the tetracycline-inducible promoter and subsequent proteomic analysis of GFP-interacting proteins. We include a list of proteins that were identified as interactors of GFP.

1. Introduction

Ectopic introduction of an inducible GFP-tagged protein in cells is a useful technique for characterization of protein-protein interactions. Introduction of a pcDNA-5/FRT/TOTM expression vector (Invitrogen) GFP-tagged gene with a pOG44 Flip-recombinase expression plasmid into Flp-INTM T-RExTM 293 cells (Invitrogen) will integrate the tagged gene into a single pre-designated FRT site. Following integration of the GFP-tagged gene, cells are treated with hygromycin to select for cells that have successfully integrated the pcDNA 5/FRT/TO vector containing the gene of interest.

Cells are then maintained in growth medium supplemented with hygromycin. The stable integration of GFP-tagged genes in T-RexTM 293 cells allows for real-time detection of protein expression and troubleshooting for appropriate induction time and dose of doxycycline or tetracycline. Once stable cells are established, a time-course of doxycycline or tetracycline can be performed to determine appropriate duration to achieve desired levels of protein expression (Figure 1).

Purification of GFP or GFP-tagged proteins in complex is performed in concert with the addition of dithiobis succinimidyl propionate (DSP) during lysis. DSP has dual NHS esters (see DSP structure in Figure 2), thus targeting primary amines in protein complexes and forming a conjugated network of proteins (3, 4). Lysis buffer is gently supplemented with DSP prior to lysis in a dropwise fashion to minimize precipitation, appropriate amount of lysis buffer is then added to cells and allows DSP to interact with primary amines in proteins and complexes of the proteins. Figure 3 illustrates a graphical representation of the pull-down workflow and protein identification by mass spectrometry.

2. Materials

1. T-REx 293 cell lines are available from Invitrogen (R780-07). Maintain cells in DMEM supplemented with 10% fetal bovine serum (FBS, Hyclone), 2 mM L-glutamine (Gibco), 100 U/ml penicillin, 200 µg/ml streptomycin, 15 µg/ml blasticidin and 100 µg/ml zeocin.
2. Recombinase Flp-IN pOG44 (V6005-20) and pCDNA5 FRT/TO (V6520-20) can be purchased from Invitrogen.
3. Clone individual genes of interest into pCDNA5 FRT/TO using convenient

multiple cloning sites.

4. Lysis buffer is prepared as 40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 50 mM NaF, 1.5 mM sodium orthovanadate, 1% Triton, 1 tablet complete protease inhibitor cocktail per 25 ml (5).
5. Prepare dithiobis succinimidyl propionate (DSP, Pierce) 200 mg/ml in dimethyl sulfoxide (prepare fresh). DSP forms an NHS ester with primary amines and is cleaved upon reduction with dithiothreitol (DTT). This property allows for purification of conjugated DSP-protein complexes and release upon addition of the reducing agent in the final steps just prior to performing SDS-PAGE.
6. Equilibrate GFP-trap beads (ChromoTek) in lysis buffer (above). Finally, prepare 50% slurry.
7. 1.5 mm NuPAGE Bis-Tris 10% precast gels (Invitrogen).
8. MOPS SDS-PAGE running buffer (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7).
9. Spin X columns Corning[®] Costar[®] Spin-X[®] centrifuge tube filters cellulose acetate membrane, pore size 0.45 μ m, sterile.
10. SimplyBlue[™] SafeStain (Invitrogen)
11. Triethylammonium bicarbonate (Sigma)
12. Sequencing grade modified trypsin (Promega)

3.1 Transfection and establishing a GFP stable cell line

1. Plate $\sim 1 \times 10^6$ ($\sim 60\%$ confluent) in a 10-cm dish in complete medium lacking zeocin/blastidin. Place cells in a 37°C, 5% CO₂ incubator overnight.

2. Pre-warm 1 ml of Opti-MEM serum free medium (Life Technologies) in a 15-ml conical tube.
3. Add 9 μg pOG44 plasmid and 1 μg of pCDNA5/FRT/TO-GFP vector (Note: maintain a 9:1 ratio of pOG44 with pCDNA5/FRT/TO-GFP when scaling target cell dish size).
4. Add 25 μl of polyethylenimine (1 mg/ml) (Polysciences) or other transfection reagent to transfection medium and mix by tapping or vortexing for 15 s
5. Leave the transfection mix for 15 min at room temperature.
6. Add the entire transfection mixture to the target cell dish in a drop-wise fashion and return cells to the incubator.
7. 24 h post-transfection split cells into 3 dishes and maintain in DMEM, 10% FBS, L-glutamine, penicillin and streptomycin for 24 h.
8. Exchange medium with fresh medium containing 15 $\mu\text{g/ml}$ blasticidin and 100 $\mu\text{g/ml}$ hygromycin. Hygromycin selection will cause the death of untransfected cells lacking the integration of pCDNA5/FRT/TO/GFP vector into the FRT site. Replace medium every three days. As a negative control, use the selection medium in untransfected control cells.
9. Check cells daily until majority of cells are dead and a number of colonies have formed. Then begin the expansion of cells for protein expression analysis.
10. Test doxycycline (20 ng/ml) or tetracycline (1 $\mu\text{g/ml}$) induction time course (Figure 1) for GFP-expression. Fluorescence microscopy can also be used to ensure that every cell expresses GFP upon induction with doxycycline or tetracycline.

3.2 Purification of GFP-interacting proteins from stable cell lines using DSP crosslinking agent

1. Induce GFP protein expression with 20 ng/ml doxycycline for a defined time.
2. Wash cells once in ice-cold PBS. Gently add PBS to prevent dislodging cells during washing steps.
3. Lyse by scraping the desired number and size (10cm-15cm) of semi-confluent dishes in complete lysis buffer (above) with 2.5 mg/ml DSP. Transfer lysates onto a falcon tube.
4. Keep the lysates on ice for 30 minutes, then quench crosslinking reaction by adding 6.25 ml of 1M Tris-HCl, pH 7.4 per 25ml lysis buffer (200 mM Tris-HCl final) and incubate for further 30 minutes. (Lysates can be snap frozen in liquid nitrogen and stored at -80 °C this stage)
5. Spin lysates at 10,000 x g for 30 min at 4 °C. Collect a small aliquot of cleared lysate for immunoblot analysis.
6. Filter the lysates through a filter column to clear the lysate of any debris.
7. To clarified lysate, add 50 µl packed sepharose or agarose beads for 1h at 4 °C. This pre-clearing step minimizes non-specific interactions to solid-phase.
8. To the cleared lysate (10-60 mg total protein), add 50 µl of equilibrated GFP-rap beads and incubate for 4 h on a roller at 4°C.
9. Wash beads in 4 x 10 ml of complete lysis buffer containing 0.5M NaCl. Addition of NaCl removes weak or low affinity spurious interactions.
10. Wash beads with 10 ml of 50 mM Tris-HCl, pH 7.5, 0.1mM EGTA.
11. Reconstitute beads in 60 µl of 1X LDS sample buffer with 0.1M DTT final, incubate for 1 h at 37 °C, boil for 5 min at 95 °C. DTT reduces disulfide bond from DSP to remove cross-linking of proteins.

12. Isolate denatured proteins from GFP-trap beads by spinning through spin X columns.

3.3 Gel electrophoresis of GFP purified protein complexes

1. Prepare a 10% NuPAGE Bis-Tris (1.5 mm thick) gel for electrophoretic separation of proteins. Rinse wells thoroughly with MOPS running buffer.
2. Load equal amounts of control GFP and GFP-protein of interest into alternating wells (leave empty wells between samples to minimize potential cross contamination during loading).
3. Resolve proteins at ~160 volts for ~45 minutes.
4. Stain using mass spectrometry grade staining reagent containing Coomassie blue dye or Simply Blue.
5. Image gel in clean petri dish, avoid unnecessary handling to minimize keratin contamination.

4.1 In gel Trypsin digestion

1. Excise bands of interest for each sample lane (See example Figure 4A).
2. Cut bands into small 1-2 mm cubes with a clean scalpel. Place into clean 1.5 ml centrifuge tubes, minimize keratin contamination by changing gloves frequently.
3. Wash gel bands sequentially in 500 μ l of 1) water, 2) 50% acetonitrile, 3) 50 mM NH_4HCO_3 (ammomium bicarbonate; prepared fresh) and 4) 50% acetonitrile/50 mM NH_4HCO_3 . Place samples on shaker for 10 min at room temperature for each wash step. Aspirate wash solution after each step.
4. In-gel alkylation and reduction steps:

- a. To each tube add 75 μ l of freshly prepared 10 mM DTT/50 mM NH_4HCO_3 and incubate for 20 minutes at 37°C. Remove solution and proceed to alkylation step.
 - b. Add 75 μ l of freshly prepared 100 mM iodoacetamide/50 mM NH_4HCO_3 and incubate in dark at room temperature for 20 min.
6. Remove liquid and wash bands in 50 mM NH_4HCO_3 for 10 min at room temperature.
7. Remove liquid and replace with 50% acetonitrile/50 mM NH_4HCO_3 to remove any dye stain. Repeat wash steps until gel pieces are colorless.
8. Add 300 μ l of acetonitrile to each tube for 10-15 minutes. Speed vacuum away additional acetonitrile, dry gel pieces will appear opaque.
9. Re-swell gel pieces in 25 mM triethylammonium bicarbonate containing 5 μ g/ml of sequencing grade modified porcine trypsin. Place on shaker at 30 °C. After 20-30 minutes, check gel pieces are adequately soaked in solution. If not, add more triethylammonium bicarbonate to assure coverage of bands. Digest gel bands overnight.
10. Following overnight digest, add an equivalent volume of acetonitrile to each gel piece and shake for 10-15 minutes.
11. Transfer supernatant onto a clean tube. Place directly into vacuum centrifuge and spin until dry.
12. To gel pieces, add additional 100 μ l of 50% acetonitrile/2.5% formic acid and shake. Add supernatant to dried tubes from step 11. Transfer tubes to vacuum centrifuge until dry. Samples are now ready for 1-dimensional HPLC electrospray ionization. Samples can be stored at -80 °C until ready to perform mass spectrometry analysis.

4.2 Mass spectrometry

1. Solubilize digested peptide samples into a working volume of HPLC grade 5% acetonitrile/0.1% formic acid for injection into the HPLC autosampler, typically 20-30 μ l volumes are reasonable.
2. Resulting peptides are injected onto a 3- μ m C₁₈ reversed-phase (RP) resin column (Acclaim PepMap100, 75 μ m \times 15 cm). Peptides are eluted into a Thermo LTQ Orbitrap over a 40-minute gradient of 2% acetonitrile/0.1% formic acid to 50% of a 90% acetonitrile/0.08% formic acid solvent.
3. Spectra are collected under data-dependent analysis selecting for the 5 most intense MS ions to be fragmented for MS-MS sequencing (See Figure 4B for example). Depending on instrumentation, additional ion fragmentation can be integrated into the data-dependent analysis. Exclusion lists for repeat ions can be developed to increase spectral analysis.
4. Raw data files/spectra can be submitted to in-house proprietary (Mascot, Sequest Sorcerer) or non-proprietary (Global proteome machine analysis www.gpm.org) database search softwares. Once spectra have been assigned and proteins identified, the lists of interacting proteins can be interrogated using ontological and cluster analysis softwares (see section 4.3). Quantitative analysis can be performed using Scaffold, a statistical package for determination of data quality and spectral assignments (6).

4.3 Bioinformatics analysis of dataset

Analysis of shotgun proteomics lists can be conducted using proprietary software such as Ingenuity Pathways Analysis or public databases such as the Database for Annotation, Visualization and Integrated Discovery (DAVID,

<http://david.abcc.ncifcrf.gov>) (7, 8). These software packages allow for delving into the dataset and assigning molecular function and disease correlation along with developing various other ontological connections within the dataset. Gene Ontology (geneontology.org) can also be used to interrogate and determine term enrichment within a dataset (9). Cell localization, function and disease associations can be assigned to groups of proteins to better understand characteristics of the proteome cohort (10). Solid phase interactors (i.e. GFP binders) can be compared to the CRAPome database of non-specific interactors as well (crapome.org) (5). This repository is useful towards determining ruling out non-specific interactions.

Notes and Conclusions:

Affinity purification of target protein complexes provides a convenient way to identify novel binding partners involved in biological processes. Inclusion of GFP tags allows for determination of transfection efficiency by visualization. One caveat is the effect of the large tag on native interactions. Considering this caveat, a strategy to tag target proteins either at the N or C terminus or alternatively at an internal site could provide insight into the effects of GFP fusion on native protein interactions. Careful determination of the induction time for the GFP fusion protein should be considered for potential spurious interactions due to heightened overexpression and effects of high abundance peptides masking identification of lower abundance but biologically important interactions. Using another method of fractionation can improve proteome identification and minimize dampening of signal for low abundance peptides (i.e. strong cation or strong anion HPLC fractionation of peptides or size

exclusion chromatography of proteins prior to tryptic digestion). The identification of protein complexes can yield a great deal of information in terms of protein function and involvement in biological processes. The above protocol provides a detailed approach towards conducting protein network characterization using mass spectrometry based technologies. The inclusion of a list of human proteins that interact with GFP under the experimental conditions described above will allow researchers to exclude these as contaminants in similar proteomic approach looking at potential interactors of GFP-tagged proteins (Table 1).

We have employed the above methodology routinely for many proteomic studies (11-14) and continue to do so. Affinity purification of protein complexes and analysis by mass-spectrometry is a widely used technique and so variations to the above methodology also exist.

Acknowledgements:

We thank Kirsten McLeod and Janis Stark for help with tissue culture, Thomas Macartney for cloning pCDNA5/FRT/TO/GFP, and the staff at the Sequencing Service (School of Life Sciences, University of Dundee, Scotland) for DNA sequencing. We thank Dave Campbell and the mass-spectrometric team at the MRC Protein Phosphorylation and Ubiquitylation Unit for optimization of protocols relating to sample processing for mass-spectrometry. TDC is supported by the UK MRC Career Development Fellowship. GS is supported by the UK Medical Research Council and the pharmaceutical

companies supporting the DSTT (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck-Serono, Pfizer and Johnson & Johnson).

References:

- (1) Huang, B.X., and Kim, H.Y. (2013) Effective identification of Akt interacting proteins by two-step chemical crosslinking, co-immunoprecipitation and mass spectrometry. *PloS one*. **8**, e61430
- (2) Gao, M., McCluskey, P., Loganathan, S.N., and Arkov, A.L. (2014) An in vivo crosslinking approach to isolate protein complexes from Drosophila embryos. *Journal of visualized experiments : JoVE*.
- (3) Kim, K.M., Yi, E.C., and Kim, Y. (2012) Mapping protein receptor-ligand interactions via in vivo chemical crosslinking, affinity purification, and differential mass spectrometry. *Methods*. **56**, 161-165
- (4) Corgiat, B.A., Nordman, J.C., and Kabbani, N. (2014) Chemical crosslinkers enhance detection of receptor interactomes. *Frontiers in pharmacology*. **4**, 171
- (5) Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., Li, T., Miteva, Y.V., Hauri, S., Sardiu, M.E., Low, T.Y., Halim, V.A., Bagshaw, R.D., Hubner, N.C., Al-Hakim, A., Bouchard, A., Faubert, D., Fermin, D., Dunham, W.H., Goudreault, M., Lin, Z.Y., Badillo, B.G., Pawson, T., Durocher, D., Coulombe, B., Aebersold, R., Superti-Furga, G., Colinge, J., Heck, A.J., Choi, H., Gstaiger, M., Mohammed, S., Cristea, I.M., Bennett, K.L., Washburn, M.P., Raught, B., Ewing, R.M., Gingras, A.C., and Nesvizhskii, A.I. (2013) The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. *Nature methods*. **10**, 730-736
- (6) Searle, B.C. (2010) Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. *Proteomics*. **10**, 1265-1269
- (7) Yang, L.J., Ma, D.Q., and Cui, H. (2014) Proteomic analysis of immature rat pups brain in response to hypoxia and ischemia challenge. *International journal of clinical and experimental pathology*. **7**, 4645-4660
- (8) Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature protocols*. **4**, 44-57
- (9) Carnielli, C.M., Winck, F.V., and Paes Leme, A.F. (2015) Functional annotation and biological interpretation of proteomics data. *Biochimica et biophysica acta*. **1854**, 46-54
- (10) Pawar, H., Kashyap, M.K., Sahasrabudde, N.A., Renuse, S., Harsha, H.C., Kumar, P., Sharma, J., Kandasamy, K., Marimuthu, A., Nair, B., Rajagopalan, S., Maharudraiah, J., Premalatha, C.S., Kumar, K.V., Vijayakumar, M., Chaerkady, R., Prasad, T.S., Kumar, R.V., Kumar, R.V., and Pandey, A. (2011) Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. *Cancer biology & therapy*. **12**, 510-522
- (11) Vogt, J., Dingwell, K.S., Herhaus, L., Gourlay, R., Macartney, T., Campbell, D., Smith, J.C., and Sapkota, G.P. (2014) Protein associated with SMAD1 (PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein

- receptors and modulates bone morphogenetic protein signalling. *Open biology*. **4**, 130210
- (12) Al-Salihi, M.A., Herhaus, L., Macartney, T., and Sapkota, G.P. (2012) USP11 augments TGFbeta signalling by deubiquitylating ALK5. *Open biology*. **2**, 120063
- (13) Herhaus, L., Al-Salihi, M., Macartney, T., Weidlich, S., and Sapkota, G.P. (2013) OTUB1 enhances TGFbeta signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3. *Nature communications*. **4**, 2519
- (14) Herhaus, L., Al-Salihi, M.A., Dingwell, K.S., Cummins, T.D., Wasmus, L., Vogt, J., Ewan, R., Bruce, D., Macartney, T., Weidlich, S., Smith, J.C., and Sapkota, G.P. (2014) USP15 targets ALK3/BMPRI1A for deubiquitylation to enhance bone morphogenetic protein signalling. *Open biology*. **4**, 140065

Figure Legends

Figure 1. A time course of doxycycline induction of GFP-expression in T-Rex 293 GFP cells. Establishing a time course of robust induction of the target protein to determine appropriate amount of protein production for interaction analysis. Here 6-16 hours of doxycycline induction is appropriate to perform protein isolation and downstream mass spectrometry analysis.

Figure 2. Dithiobis (succinimidyl propionate): In blue brackets indicates carbodiimide that reacts with primary amines releasing the NHS ring while cross-linking polypeptides, red disulfide bond indicates bond that reacts with reducing reagent to cleave linkage and release cross-linked proteins or polypeptides.

Figure 3. Schematic work-flow for GFP-trap purification and mass spectrometry analysis of co-purified proteins.

Figure 4. A. Affinity-purified GFP was resolved by SDS-PAGE electrophoresis with molecular weight markers (kDa) indicated in the first lane. Brackets indicate one excised gel-piece, which was tryptically digested for mass spectrometric electrospray analysis. B. Identification of a prominent protein from the 100 kDa excised band in GFP lane. GFP interactors are compared to target protein of interest to exclude non-specific GFP or bead interacting proteins. Included in Table 1 are highly enriched promiscuous GFP contaminants that can be excluded from target protein pulldown analysis.

Table 1. GFP-binding proteins in a DSP cross-linked pulldown experiment. Proteins are rank ordered by normalized spectral count enrichment using Scaffold software (v.4.2.1).

FIGURE 1.







FIGURE 2.



A.



B.



GTF2I_HUMAN (100%, 112,417.9 Da)
 General transcription factor II-I OS=Homo sapiens GN=GTF2I PE=1 SV=2
 62 exclusive unique peptides, 94 exclusive unique spectra, 219 total spectra, 608/998 amino acids (61% coverage)

MAQVAMSTLP	VEDEESSSES	MVVTFLMSAL	ESMCKELAKS	KAEVACIAVY
ETDVFVVGTE	RGRAFVNTRK	DFQKDFVKYC	VEEEEKAAEM	HMKKSTTOAN
RM ⁵ SVDAVEIE	TLRKTVEDYF	CFCYGKALGK	STVVPVPYEK	MLR ¹⁰ DQSAVVV
QGLPEGVAFK	HPENYDLATL	KWILENKAGI	SFI ¹ IKRPFLE	PKKHVGGRVM
VTDA ¹ DRSILS	PGGSCGPIKV	KTEPTEDSGI	SLEMAAVTVK	EES ¹ EDPDY ¹ YQ
YNIQAGPSET	DDVDEKQPLS	KPLQGS ¹ HSS	EGNEGTEMEV	PAEDSTQHPV
SETSEDP ¹ EV	VTIEDDDYSP	PSKRPKANEL	PQPPVPEPAN	AGKRK ¹ VREFN
FEKWNARITD	LRKQVEELFE	RKYAQAIKAK	GPVTIPYPLF	QSHVEDLYVE
GLPEGIPFRR	PSTYGI ¹ PRLE	RILLAKERIR	FVIKKHELLN	STREDLQLDK
PASGVK ¹ EEWY	ARITKLRKMV	DQLFCKKFAE	ALGST ¹ EAKAV	PYQKFEAHPN
DLYVEGLPEN	IPFRSPSWYG	IPRLEKIIQV	GNRIK ¹ FVIKR	PELLTHSTTE
VTQPR ¹ TNTPV	KEDWNV ¹ ITK	LRKQVEE ¹ IFN	LKFAQALGLT	EAVK ¹ VPYPVF
ESNPEFLYVE	GLPEGIPFRS	PTWFGIPRLE	RIVRGS ¹ NKIK	FVVKK ¹ PELVI
SYLPPGMASK	INTKALQSPK	RPRS ¹ SPGSNSK	VPEIEV ¹ TVEG	PNNNN ¹ PQTS ¹ SA
VRTPTQTNGS	NVPFK ¹ PRGRE	FSFEAWNAKI	TDLKQ ¹ KVENL	FNEK ¹ CGEALG
LKQAVK ¹ VPFA	LFESF ¹ PEDFY	VEGLPE ¹ GVVPF	RRPST ¹ FGIPR	LEKIL ¹ RNKAK
IKFI ¹ IKKPEM	FETA ¹ IKESTS	SKSP ¹ PRKINS	SPNVNT ¹ TASG	VEDLN ¹ IIQVT
IPDD ¹ DNERLS	KVEKAR ¹ QLRE	QVNDL ¹ FSRKF	GEAIG ¹ MGF ¹ FPV	KV ¹ PYRKITIN
PGCV ¹ VVDGMP	PGVS ¹ FKAPSY	LEISS ¹ MRRIL	DSAE ¹ FIKFTV	IRPF ¹ PGLVIN
NQLVD ¹ QSESE	GPVI ¹ QESAEP	SQLE ¹ VPATEE	IKET ¹ DGSSQI	KQEP ¹ DP ¹ TW

FIGURE 4.

Table 1.

Gene Symbol	Spectral Count (Normalized)	MW (kDa)
ACTN4	233.77	105
EPPK1	204.55	556
PLEC	204.55	532
GTF2I	175.33	112
PRDX1	146.11	22
YWHAZ	146.11	28
DSG1	146.11	114
EEF1A1	116.89	50
YWHAE	116.89	29
GRP78	116.89	72
RPS27A	116.89	18
UBA52	116.89	15
ENO1	116.89	47
GNB2L1	116.89	35
ALB	116.89	69
KRT77	116.89	62
EEF1A2	87.664	50
ACTN1	87.664	103
TUFM	87.664	50
RPS3	87.664	27
NONO	87.664	54
SF3B3	87.664	136
PCMT1	87.664	25
ACLY	87.664	121
VCL	87.664	124
PDIA6	87.664	48
GRP94	87.664	92
MCM6	87.664	93
NUP98	87.664	198
PRDX4	87.664	31
PCCB	87.664	58
TPI1	87.664	31
HNRNPUL1	87.664	96
PDAP1	87.664	21
CLTC	58.443	192
ACTG1	58.443	42
SPTAN1	58.443	285
EPRS	58.443	171
SPTBN1	58.443	275
NUP214	58.443	214
RANBP2	58.443	358
HNRNPM	58.443	78
GART	58.443	108
HSPD1	58.443	61
NUP155	58.443	155
PRDX2	58.443	22
MTHFD1	58.443	102
HNRNPU	58.443	91
CCT4	58.443	58
TCP1	58.443	60
HNRNPA1	58.443	39
YWHAH	58.443	28
KHSRP	58.443	73
SND1	58.443	102

Gene Symbol	Spectral Count (Normalized)	MW (kDa)
HNRNPA2B1	58.443	37
MARS	58.443	101
NUP93	58.443	93
NUMA1	58.443	238
PHGDH	58.443	57
GDI1	58.443	51
YWHAG	58.443	28
PSMA7	58.443	28
TPM3	58.443	33
USP5	58.443	96
NUP107	58.443	106
RAE1	58.443	41
PRPF6	58.443	107
TAGLN2	58.443	22
RPL11	58.443	20
SDHB	58.443	?
AARS	58.443	107
HIST1H4A	58.443	11
RAB5C	58.443	23
MIF	58.443	12
MOV10	58.443	114
UHRF1	58.443	90
FUBP1	58.443	68
ACTC1	29.221	42
ACTA1	29.221	42
ACTBL2	29.221	42
POTEE	29.221	121
USP9X	29.221	292
CSNK1D	29.221	47
CNOT1	29.221	267
CCT2	29.221	57
ATP5A1	29.221	60
CCT8	29.221	60
EIF4A1	29.221	46
EIF4A2	29.221	46
MCM3	29.221	91
MCM7	29.221	81
DDB1	29.221	127
PABPC4	29.221	71
PABPC1	29.221	71
NUP205	29.221	228
SMC3	29.221	142
PARP1	29.221	113
NUP188	29.221	196
PSMD1	29.221	106
RAD50	29.221	154
GAPDH	29.221	36
PSMC5	29.221	46
MCM4	29.221	97
VCP	29.221	89
LARS	29.221	134
IKBKAP	29.221	150
DARS	29.221	57
SFPQ	29.221	76

Gene Symbol	Spectral Count (Normalized)	MW (kDa)
SFPQ	29.221	76
AHCY	29.221	48
SMC4	29.221	147
KRT18	29.221	48
DDX5	29.221	69
MYO6	29.221	150
UBA1	29.221	118
YWHAQ	29.221	28
SDHA	29.221	?
RPS4X	29.221	30
DNAJC7	29.221	56
CSDE1	29.221	89
UBAP2L	29.221	115
LDHB	29.221	37
NUP88	29.221	84
RPSA	29.221	33
CDC5L	29.221	92
PCNA	29.221	29
UPF1	29.221	124
GDI2	29.221	51
COPB2	29.221	102
PHB2	29.221	33
HDLBP	29.221	141
PDIA3	29.221	57
ADAR	29.221	136
RTCB	29.221	55
ADE2/PAICS	29.221	47
ALDH18A1	29.221	87
PSMB5	29.221	28
SHMT2	29.221	56
DDX1	29.221	82
FKBP4	29.221	52
RPS3A	29.221	30
MST4	29.221	47
FAM115A	29.221	102
OGT1	29.221	117
HNRNPH1	29.221	49
TPM4	29.221	29
NPEPPS	29.221	103
KIF11	29.221	119
RPL4	29.221	48
PUM1	29.221	126
TARS	29.221	83
ALDOA	29.221	39
RAN	29.221	24
RPS11	29.221	18
DIAPH1	29.221	141
HNRNPA3	29.221	40
NAP1L1	29.221	45
BUB3	29.221	37
PDCD6IP	29.221	96
RPL10A	29.221	25
RPS8	29.221	24
LDHA	29.221	37

Table 1. Cont'd

Gene Symbol	Spectral Count (Normalized)	MW (kDa)
ABCE1	29.221	67
ILF3	29.221	95
DNAJC10	29.221	91
KRT31	29.221	47
KRT35	29.221	50
KRT33B	29.221	46
KRT33A	29.221	46
C14orf166	29.221	28
HSD17B10	29.221	27
RPL17	29.221	21
SERPINB4	29.221	45
PRDX6	29.221	25
SERPINB6	29.221	43
SARS2	29.221	58
EPS15	29.221	99
HNRNPH2	29.221	49
DPYSL2	29.221	62
PRDX3	29.221	28
DDX42	29.221	103
TBCE	29.221	59
CSRP2	29.221	21
CKAP4	29.221	66
RBM39	29.221	59
EIF6	29.221	27
PMPCB	29.221	54
RPL13A	29.221	24
CSTF1	29.221	48
PPA1	29.221	33
MICAL1	29.221	118
TFAM	29.221	29
SEC22B	29.221	25
JUP	29.221	82
PPIF	29.221	22
TBCB	29.221	27
ST13	29.221	41
SYNCRIP	29.221	70
CBX3	29.221	21
RPL19	29.221	23
RANBP1	29.221	23
RPL28	29.221	16
PFN1	29.221	15
RBM10	29.221	104
LMNB2	29.221	68
RPL17	29.221	21
SERPINB4	29.221	45
PRDX6	29.221	25
SERPINB6	29.221	43
SARS2	29.221	58
EPS15	29.221	99
HNRNPH2	29.221	49
DPYSL2	29.221	62
PRDX3	29.221	28
DDX42	29.221	103
TBCE	29.221	59
CSRP2	29.221	21

Gene Symbol	Spectral Count (Normalized)	MW (kDa)
CKAP4	29.221	66
RBM39	29.221	59
EIF6	29.221	27
PMPCB	29.221	54
RPL13A	29.221	24
CSTF1	29.221	48
PPA1	29.221	33
MICAL1	29.221	118
TFAM	29.221	29
SEC22B	29.221	25
JUP	29.221	82
PPIF	29.221	22
TBCB	29.221	27
ST13	29.221	41
SYNCRIP	29.221	70
CBX3	29.221	21
RPL19	29.221	23
RANBP1	29.221	23
RPL28	29.221	16
PFN1	29.221	15
RBM10	29.221	104
LMNB2	29.221	68
HIST1H1E	29.221	22
ACAA2	29.221	42
HNRNPR	29.221	71
PDE12	29.221	67
SF3B4	29.221	44
UBE2N	29.221	17
LIG3	29.221	113
ERAL1	29.221	48
CARS	29.221	85
UCHL3	29.221	26
SCYL2	29.221	104
CBX1	29.221	21
ERO1L	29.221	54